Samarth Kulkarni - 24 Jun 2026 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Reporting relationship: Director
Issuer ticker: CNTA
Reported as of: 24 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 16:15:21 UTC
Prior SEC filing: 03 Jun 2026
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Raphael Deferiere, attorney-in-fact

Key filing fact

Samarth Kulkarni filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 24 Jun 2026.

Key facts

This page summarizes Samarth Kulkarni's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 16:15.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001682019 Primary reporting owner

Kulkarni Samarth

Relationship: Director
Address: C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM
Signature: /s/ Raphael Deferiere, attorney-in-fact
Signature date: 24 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTA transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -208,474
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 208,474
Exercise price: $5.84
Footnotes: F1, F2, F3

CNTA transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -48,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 48,000
Exercise price: $4.87
Footnotes: F1, F2, F3

CNTA transaction Derivative

Share Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -40,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 40,000
Exercise price: $12.43
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Samarth Kulkarni is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").

Footnote F2

Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.

Footnote F3

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC remarks

Exhibit 24.2 - Substitute Power of Attorney